Ovarian cancer is the most lethal gynecologic malignancy and is usually diagnosed after becomes locally advanced, Over the last few decades, the use of interval surgery after a few cycles of neoadjuvant chemotherapy in patients with irresectable disease (stage IIIC/IV) has been proposed to increase the rate of the optimal debulking and reduce the complications. Until the beginning of this century, ovarian cancer surgery was strictly conducted via an exploratory laparotomy. As the laparoscopic approach gained acceptance in gynecology and its utility expanded to ovarian cancer surgery as well. Initially this was limited to management of early-stage disease and assessment of resectability in advanced disease, but now expanded to cytoreduction of locally advanced ovarian cancer, we conducted a prospective cohort study to evaluate the feasibility and operative safety of laparoscopic cytoreduction in locally advanced epithelial ovarian cancer post neoadjuvant chemotherapy. AIM OF THE WORK: This work aims to evaluate the feasibility and operative safety of laparoscopic cytoreduction in locally advanced epithelial ovarian cancer post neoadjuvant chemotherapy. Patients and Methods: All patients diagnosed with locally advanced epithelial ovarian cancer who received Neoadjuvant chemotherapy and showed complete or partial clinical response, followed by laparoscopic cytoreduction in the National Cancer Institute (NCI), Cairo University (CU), during the period from august 2019 to august 2021. Results: During the study period, 23 patients met the inclusion criteria and were included in the study, after exclusion of 2 patients who underwent open cytoreduction, the 23 patients underwent complete laparoscopic cytoreduction, and with Conversion rate of 8 %. (2 patients underwent open cytoreduction). Conclusion: Our study suggests that laparoscopic cytoreduction for advanced ovarian cancer post neoadjuvant CTH is feasible and safe in term of perioperative outcomes.